Pre-Conference Workshop

Share developments in the conversation around operationalization of innovative agreements for pharmaceutical reimbursement including:

1. Findings of recent national, multi-stakeholder workshops on Outcomes-Based Agreements (OBA) in Canada including shared high-level goals and observations to inform implementation
2. Discussion of major stakeholder perspectives on pan-Canadian implementation.

1:00 pm | Welcome & Overview

Kate Harback, CEO, Institute for Health Economics

1:05 pm | Introductory Remarks

Graham Statt, Chief Administrative Officer, District of Summerland

1:15 pm | Presentation: INESSS Perspective on Alternative Economic Scenarios

Speaker: Mélanie Caron, Directrice Adjointe, Direction de l’évaluation des médicaments et des technologies à des fins de remboursement, Institut national d'excellence en santé et en services sociaux (INESSS)

1:45 pm | Presentation: Practical Considerations for Outcome Based Agreements

Joshua Dube, Senior Health Economist, pan-Canadian Pharmaceutical Alliance

1:55 pm | Presentation: Findings from the Operationalizing Innovative Managed Entry Agreements in Canada Workshop held in October 2023, in Toronto, Ontario (CAPT Annual Conference)

Speaker: Kate Harback, CEO, Institute for Health Economics

2:10 pm | Presentation: Findings from the What Criteria? – A Discussion of Best Circumstances for the Application of Outcomes Based Agreements Workshop held in February 2024 in Edmonton, Alberta (CAHR Western Day)

Speaker: Jeff Round, Chief Scientific Officer, Institute for Health Economics

2:30 pm | Break

3:00 pm | Discussion: Innovative Agreements in a Pan-Canadian Environment

Speakers:

• Doug Clark, CEO, pan-Canadian Pharmaceutical Alliance (pCPA)
• Heather Logan, Vice-President, Strategic Relationships and Initiatives, Canada’s Drug and Health Technology Agency (CADTH)
• Berkeley Vincent, President, Johnson & Johnson Innovative Medicines
• Beth Kidd, Executive Director, Health Coalition of Alberta

Moderator: Peter Jamieson, Vice President Quality and Chief Medical Officer–Interim, Alberta Health Services

4:15 pm | Closing Remarks

Philippe Hebert, General Manager, CSL Behring
Peter Jamieson, Vice President Quality and Chief Medical Officer–Interim, Alberta Health Services

Melanie Caron, Directrice Adjointe, Direction de l’évaluation des médicaments et des technologies à des fins de remboursement, Institut national d'excellence en santé et en services sociaux (INESSS)
Mrs Caron holds a Doctorate in Pharmacy (Pharm D) from Université de Montréal, as well as additional training in management and governance. She has over 20 years of management experience in various health and social services institutions and provincial organizations. She is also a fellow of the EXTRA program of the Canadian Foundation for Health Services Improvement and a member of the Ordre des pharmaciens du Quebec and the Institute of Corporate Directors of Canada. After a term as special advisor in pharmacy and virtual care to the Quebec Ministry of Health and Social Services, she joined INESSS in 2022.

Doug Clark, CEO, pan-Canadian Pharmaceutical Alliance
Doug Clark was appointed chief executive officer of the pan-Canadian Pharmaceutical Alliance (pCPA) in September 2023. Prior to joining the pCPA, Doug served as a senior executive in the federal government, most recently as executive director of the Patented Medicine Prices Review Board and before that, as assistant deputy commissioner with the Competition Bureau. Over the span of his 25-year career in the public service, Doug led a wide range of significant pharmaceutical policy and regulatory initiatives and acquired a deep and diverse understanding of the pharmaceutical landscape in Canada. Doug holds a BA and LLB and was called to the Ontario Bar in 1999.

Josh Dubé, Senior Economist, pan-Canadian Pharmaceutical Alliance
Josh Dubé is a Senior Economist at the pan-Canadian Pharmaceutical Alliance (pCPA). He has over five years of experience in health economics and market access that spans consulting, health technology assessment (CADTH), and payer negotiations. Josh did his Masters of Biotechnology at the University of Toronto.

Kate Harback, CEO, Institute of Health Economics
Prior to appointment as CEO, Dr Harback served as the Director of Economics at the Institute of Health Economics. Kate has 20 years of experience leading research for diverse stakeholders in Canada and the United States. Prior to working in health, she worked in the fields of aviation, space traffic, freight rail, among other major infrastructure fields at the MITRE Corporation. Kate did her PhD in economics at the University of Delaware.

Philippe Hébert, General Manager, CSL Behring Canada
Philippe Hébert is a seasoned business leader with a career spanning over four decades in the pharmaceutical industry. Serving as the General Manager at CSL Behring for the past ten years, Philippe oversees commercial operations in Canada which are focused on rare diseases, including primary & secondary immunodeficiency, hereditary angioedema, hemophilia, and neuro-muscular diseases. Most recently Philippe and his team have been working with Canadian stakeholders to provide patient access to an innovative gene therapy called Hemgenix®, for the treatment of Hemophilia B which received a Health Canada Notice of Compliance in October 2023. Prior to his current role, Philippe held pivotal positions at Merck Canada including Vice-President of Corporate Strategic Planning, Vice-President of Marketing & Planning and Vice-President & Business Unit head for the Cardiovascular Portfolio. In addition, he has gained substantial national and international experience while working at other innovative manufacturers including Covidien and Mallinckrodt Pharmaceuticals. Throughout his education and career, which includes a Bachelor of Pharmacy Degree from the University of Montreal, Philippe has been recognized for his strategic agility, collaborative approach, and transformative leadership style. His contributions have left an indelible mark on the industry, fostering growth and innovation while ensuring the delivery of exceptional patient care.

Peter Jamieson, Vice President Quality and Chief Medical Officer–Interim, Alberta Health Services; Canadian Drug Expert Committee, CADTH; Human Drug Advisory Panel, Patented Medicine Prices Review Board (PMPRB)
Peter Jamieson is the Interim Vice President for Quality and the Chief Medical Officer for Alberta Health Services, leading the Medical Affairs, Information Technology, Clinical Informatics, and Health Information services for AHS. He also has executive medical lead responsibilities for Cancer Care and Clinical Support Services including Pharmacy. Dr. Jamieson previously served as Associate Zone Medical Director in Calgary and as Medical Director of the Foothills Medical Centre. He is a full Clinical Professor in the Faculty of Medicine at the University of Calgary, with experience in teaching at the undergraduate, graduate, and postgraduate levels. Dr. Jamieson serves as a member of the Canadian Drug Expert Committee with the Canadian Agency for Drugs and Technology in Health, and as a member of the Human Drug Advisory Panel with the Patented Medicines Price Review Board of Canada.

Beth Kidd, Executive Director, Health Coalition of Alberta
Beth is the Executive Director of the Health Coalition of Alberta, representing more than 120 health charities, patient groups, health associations and individual members. In this capacity she advocates on priorities such as health equity, access to care, access to medications and patient engagement in health policy. Although she has worked in the corporate world, most of her career has been in the health charity sector focused on improving access to services and care. Beth is a life-long volunteer with many health charities, political parties, and community groups. She currently sits on Research Canada’s Board of Directors, is a member of CADTH’s Patient and Community Advisory Committee and the Dementia Network Calgary’s Strategic Council, and is one of the founders and moderators of Alberta’s Migraine Warriors patient support group.

Heather Logan, Vice-President, Strategic Relationships and Initiatives, CADTH
Heather Logan is Vice-President, Strategic Relationships and Initiatives, at CADTH. In addition to heading up CADTH’s Post-Market Drug Evaluation Program, Heather oversees the organization’s external engagement functions, including building meaningful partnerships and identifying innovative opportunities to strengthen CADTH’s relationships with decision-makers, patient and health care provider organizations, Indigenous Peoples and communities, the pharmaceutical and medical devices industry, and other stakeholders across pan-Canadian health systems. She is also responsible for helping the organization take meaningful action and drive sustainable culture change to support equity, diversity, and inclusion both internally and externally. With nearly 30 years of experience working with local, provincial, and national decision-makers, Heather is known for her facilitative leadership style and for being results-driven. With a background as a nursing officer in the Canadian Armed Forces, a health care administrator, and a systems leader, she brings a unique and collaborative perspective to her role at CADTH.

Jeff Round, Chief Scientific Officer, Institute of Health Economics
Jeff Round is Chief Scientific Officer at the Institute of Health Economics and Professor of Health Economics at the University of Alberta. Dr Round’s research encompasses both applied and methodological topics in health economics and economic evaluation. He has received research funding from CIHR, the UK NIHR, the Wellcome Trust, the UK MEDICAL Research Council and charitable funders in the UK and Canada. Recent applied research projects include evaluations of germline screening in advanced prostate cancer patients, newborn screening for spinal muscular atrophy and the cost-effectiveness of WHO recommended COVID therapies. Current methods research includes exploring the role of the QALY in decision making, innovative funding models for high-cost therapies and the assessment and valuation of health-related quality of life in children with rare diseases and their caregivers. Dr Round is co-lead for the Health Economics, Health Technology Assessment, & Reimbursement theme of the recently announced RareKids-CAN Pediatric Rare Disease Clinical Trials and Treatment Network.

Graham Statt, Chief Administrative Officer, District of Summerland, BC
Graham Statt is the Chief Administrative Officer for the District of Summerland, BC, leading the delivery of public utilities, services, infrastructure, and responsible development. Before his time in local government, Graham spent nearly two decades in Alberta’s public service in five different Ministries, holding three different Assistant Deputy Minister (ADM) portfolios. From 2017 to 2020 Graham was the ADM of the Pharmaceutical and Supplementary Benefits Division in Alberta Health, where he was accountable for Alberta’s Drug Formulary and government-sponsored community and specialty drug programs, the Alberta Health Care Insurance Program, and the compensation of physicians throughout the province. He led the successful negotiation of a new Pharmacy Compensation Agreement for Alberta as well the first Dental Fee Guide for Alberta in more than a decade. He also participated in key national initiatives including Canada’s Task Force for National Pharmacare and FPT health care insurance negotiations for program changes under the Canada Health Act. Graham also served as the Vice-Chair of the Pan-Canadian Pharmaceutical Alliance (PcPA), Canada’s national coordinating body for conducting collective, expert-informed negotiations for drugs.

Berkeley Vincent, President of Janssen Canada
Berkeley Vincent is the President of Janssen Inc., the Canadian Pharmaceutical Company of Johnson & Johnson. In this role, Berkeley leads the Canadian business and concurrently holds a seat on the Janssen Americas Leadership Team. Prior to this role, Berkeley was Managing Director of Janssen Nordic and the Country Director of Sweden. Under his leadership, the cluster successfully reorganized into four country-facing organizations enabling tailored and country-specific access to medicines for patients in Sweden, Denmark, Finland, and Norway. Berkeley brings a diverse set of experiences to the Canadian business, having spent more than 20 years in various roles within Janssen in the United Kingdom and Ireland, EMEA and global organizations. With increasing capacity, Berkeley led commercial businesses in core therapeutic areas of oncology, immunology, neuroscience, nephrology, and pulmonary hypertension. During the last decade he has held roles on the EMEA Strategy Leadership Team where he was responsible for the Hematology franchise, as well as the digital strategy. Berkeley currently sits on the Board of Directors for Innovative Medicines Canada (IMC) alongside other industry leaders working to shape change to improve the Canadian healthcare environment.